Does antipsychotic combination therapy reduce the risk of hospitalization in schizophrenia?

References

• McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30(1):67–76.
   PubMed Web of Science ®Google Scholar
• Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17(2):149–160.
   PubMed Web of Science ®Google Scholar
• Hjorthøj C, Stürup AE, McGrath JJ, et al. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017;4(4):295–301.
   PubMed Web of Science ®Google Scholar
• Citrome L. Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains. J Clin Psychiatry. 2014;75(Suppl 1):21–26.
   PubMed Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951.
   PubMed Web of Science ®Google Scholar
• Vermeulen J, van Rooijen G, Doedens P, et al. Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis. Psychol Med. 2017;47(13):2217–2228.
   PubMed Web of Science ®Google Scholar
• Elkis H, Buckley PF. Treatment-Resistant Schizophrenia. Psychiatr Clin North Am. 2016;39(2):239–265.
   PubMed Web of Science ®Google Scholar
• Citrome L, McEvoy JP, Saklad SR. Guide to the Management of Clozapine-Related Tolerability and Safety Concerns. Clin Schizophr Relat Psychoses. 2016;10(3):163–177.
   PubMedGoogle Scholar
• Correll C, Brevig T, Brain C. Exploration of Treatment-Resistant Schizophrenia Subtypes Based on a Survey of 204 US Psychiatrists. Neuropsychiatr Dis Treat. 2019;15:3461-3473.
   Google Scholar
• Verdoux H, Quiles C, Bachmann CJ, et al. Prescriber and institutional barriers and facilitators of clozapine use: A systematic review. Schizophr Res. 2018;201:10–19.
   PubMed Web of Science ®Google Scholar
• Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216–229.
   PubMed Web of Science ®Google Scholar
• Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry. 2017;62(11):772–777.
   PubMed Web of Science ®Google Scholar
• Faden J, Citrome L. Resistance is not futile: treatment-refractory schizophrenia - overview, evaluation and treatment. Expert Opin Pharmacother. 2019;20(1):11–24.
   PubMed Web of Science ®Google Scholar
• Sanghani SN, Petrides G, Kellner CH. Electroconvulsive therapy (ECT) in schizophrenia: a review of recent literature. Curr Opin Psychiatry. 2018;31(3):213–222.
   PubMed Web of Science ®Google Scholar
• Weissman EM. Antipsychotic prescribing practices in the veterans healthcare administration–New York metropolitan region. Schizophr Bull. 2002;28(1):31–42.
   PubMed Web of Science ®Google Scholar
• Kreyenbuhl J, Valenstein M, McCarthy JF, et al. Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophr Res. 2006;84(1):90–99.
   PubMed Web of Science ®Google Scholar
• Moore TA, Buchanan RW, Buckley PF, et al. The texas medication algorithm project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007;68(11):1751–1762.
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1–56.
   PubMed Web of Science ®Google Scholar
• International psychopharmacology algorithm project. IPAP Schizophrenia Algorithm, 2006. [cited 2020 Oct 28]. Available from: http://www.ipap.org/pdf/schiz/IPAP_Schiz_flowchart20060327.pdf
   Google Scholar
• Kreyenbuhl J, Buchanan RW, Dickerson FB, et al. Schizophrenia patient outcomes research team (PORT). The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36(1):94–103.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. Clinical guideline [CG178]. Published date: 12 February 2014. Last updated: 01 March 2014. [cited 2020 Jul 12], Available from: https://www.nice.org.uk/guidance/cg178.
   Google Scholar
• Galletly C, Castle D, Dark F, et al. Royal Australian and New Zealand college of psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):410–472.
   PubMed Web of Science ®Google Scholar
• Correll CU, Rubio JM, Inczedy-Farkas G, et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry. 2017;74(7):675–684.
   PubMed Web of Science ®Google Scholar
• Galling B, Roldán A, Hagi K, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry. 2017;16(1):77–89.
   PubMed Web of Science ®Google Scholar
• Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35(2):443–457.
   PubMed Web of Science ®Google Scholar
• Barbui C, Signoretti A, Mulè S, et al. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull. 2009;35(2):458–468.
   PubMed Web of Science ®Google Scholar
• Ortiz-Orendain J, Castiello-de Obeso S, Colunga-Lozano LE, et al. Antipsychotic combinations for schizophrenia. Cochrane Database Syst Rev. 2017;6(6):CD009005.
   PubMedGoogle Scholar
• Kim DH, Maneen MJ, Stahl SM. Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. Neurotherapeutics. 2009;6(1):78–85.
   PubMed Web of Science ®Google Scholar
• Weiner E, Conley RR, Ball MP, et al. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology. 2010;35(11):2274–2283.
   PubMed Web of Science ®Google Scholar
• Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2005;162(1):130–136.
   PubMed Web of Science ®Google Scholar
• Freudenreich O, Henderson DC, Walsh JP, et al. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res. 2007;92(1–3):90–94.
   PubMed Web of Science ®Google Scholar
• Anil Yağcioğlu AE, Kivircik Akdede BB, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry. 2005;66(1):63–72.
   PubMed Web of Science ®Google Scholar
• Honer WG, Thornton AE, Chen EY, et al. Clozapine and risperidone enhancement (CARE) study group. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med. 2006;2;354(5):472–482.
   PubMed Web of Science ®Google Scholar
• Kane JM, Correll CU, Goff DC, et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry. 2009;70(10):1348–1357.
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Heikkinen ME, Olié JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2010;13(8):1115–1125.
   PubMed Web of Science ®Google Scholar
• Henderson DC, Fan X, Copeland PM, et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol. 2009;29(2):165–169.
   PubMed Web of Science ®Google Scholar
• Englisch S, Esslinger C, Inta D, et al. Clozapine-induced obsessive-compulsive syndromes improve in combination with aripiprazole. Clin Neuropharmacol. 2009;32(4):227–229.
   PubMed Web of Science ®Google Scholar
• Schönfelder S, Schirmbeck F, Waltereit R, et al. Aripiprazole improves olanzapine-associated obsessive compulsive symptoms in schizophrenia. Clin Neuropharmacol. 2011;34(6):256–257.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Watanabe K, Uchida H, et al. Antipsychotic polypharmacy: a Japanese survey of prescribers’ attitudes and rationales. Psychiatry Res. 2013;209(3):406–411.
   PubMed Web of Science ®Google Scholar
• Sernyak MJ, Rosenheck R. Clinicians’ reasons for antipsychotic coprescribing. J Clin Psychiatry. 2004;65(12):1597–1600.
   PubMed Web of Science ®Google Scholar
• Grech P, Taylor D. Long-term antipsychotic polypharmacy: how does it start, why does it continue? Ther Adv Psychopharmacol. 2012;2(1):5–11.
   PubMedGoogle Scholar
• Correll CU, Shaikh L, Gallego JA, et al. Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. Schizophr Res. 2011;131(1–3):58–62.
   PubMed Web of Science ®Google Scholar
• Gallego JA, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138(1):18–28.
   PubMed Web of Science ®Google Scholar
• Fontanella CA, Hiance-Steelesmith DL, Guirgis H, et al. Trends in and predictors of long-term antipsychotic polypharmacy use among ohio medicaid patients with schizophrenia, 2008-2014. Psychiatr Serv. 2018;69(9):1015–1020.
   PubMed Web of Science ®Google Scholar
• Diefenderfer L. When should you consider combining 2 long-acting injectable antipsychotics? Curr Psychiatry. 2017;16(10):42–46.
   Google Scholar
• Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf. 2003;12(1):41–48.
   PubMed Web of Science ®Google Scholar
• Janssen B, Weinmann S, Berger M, et al. of polypharmacy process measures in inpatient schizophrenia care. Schizophr Bull. 2004;30(4):1023–1033.
   PubMed Web of Science ®Google Scholar
• Gören JL, Parks JJ, Ghinassi FA, et al. When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Jt Comm J Qual Patient Saf. 2008;34(10):571–582.
   PubMedGoogle Scholar
• Procyshyn RM, Honer WG, Wu TK, et al. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry. 2010;71(5):566–573.
   PubMed Web of Science ®Google Scholar
• Gallego JA, Nielsen J, De Hert M, et al. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf. 2012;11(4):527–542.
   PubMed Web of Science ®Google Scholar
• Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry. 1998;173(4):325–329.
   PubMedGoogle Scholar
• Joukamaa M, Heliövaara M, Knekt P, et al. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry. 2006;188(2):122–127.
   PubMedGoogle Scholar
• Baandrup L, Gasse C, Jensen VD, et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry. 2010;71(2):103–108.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Suokas JT, Suvisaari JM, et al. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry. 2012;69(5):476–483.
   PubMed Web of Science ®Google Scholar
• Kadra G, Stewart R, Shetty H, et al. Antipsychotic polypharmacy prescribing and risk of hospital readmission. Psychopharmacology (Berl). 2018;235(1):281–289. .
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Taipale H, Mehtälä J, et al. Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia. JAMA Psychiatry. 2019;76(5):499–507.
   PubMed Web of Science ®Google Scholar
• Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12(3):216–226.
   PubMed Web of Science ®Google Scholar
• Stahl SM, Grady MM. High-cost use of second-generation antipsychotics under California’s medicaid program. Psychiatr Serv. 2006;57(1):127–129.
   PubMed Web of Science ®Google Scholar
• Rupnow MF, Greenspan A, Gharabawi GM, et al. Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. Curr Med Res Opin. 2007;23(11):2815–2822.
   PubMed Web of Science ®Google Scholar
• Zhu B, Ascher-Svanum H, Faries DE, et al. Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry. 2008;4(8):19.
   Web of Science ®Google Scholar
• Correll CU, Gallego JA. Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice. Psychiatr Clin North Am. 2012;35(3):661–681.
   PubMed Web of Science ®Google Scholar
• Katona L, Czobor P, Bitter I. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in hungary. Schizophr Res. 2014;152(1):246–254.
   PubMed Web of Science ®Google Scholar
• Abdullah-Koolmees H, Gardarsdottir H, Minnema LA, et al. Predicting rehospitalization in patients treated with antipsychotics: a prospective observational study. Ther Adv Psychopharmacol. 2018;8(8):213–229.
   PubMed Web of Science ®Google Scholar
• Souaiby L, Gauthier C, Rieu C, et al. Clozapine and long-acting injectable antipsychotic combination: A retrospective one-year mirror-image study. Schizophr Res. 2017;188:89–91.
   PubMed Web of Science ®Google Scholar
• Se Hyun K, Dong Chung J, Yong Min A, et al. The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series. J Psychopharmacol. 2010;24(7):981–986.
   PubMed Web of Science ®Google Scholar
• Sun F, Stock EM, Copeland LA, et al. Polypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems. Am J Health Syst Pharm. 2014;71(9):728–738.
   PubMed Web of Science ®Google Scholar
• Talaslahti T, Alanen HM, Hakko H, et al. Change in antipsychotic usage pattern and risk of relapse in older patients with schizophrenia. Int J Geriatr Psychiatry. 2013;28(12):1305–1311.
   PubMed Web of Science ®Google Scholar
• Law MR, Soumerai SB, Ross-Degnan D, et al. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry. 2008;69(1):47–53.
   PubMed Web of Science ®Google Scholar
• Baker J, Aebi C. Comparison of readmission data between different categories of antipsychotic drugs at a state psychiatric hospital in Oregon. Ment Health Clin. 2018;7(3):124–130.
   PubMedGoogle Scholar
• Stroup TS, Lieberman JA, McEvoy JP, et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res. 2009;107(1):1–12.
   PubMed Web of Science ®Google Scholar
• Kreyenbuhl J, Marcus SC, West JC, et al. Adding or switching antipsychotic medications in treatment-refractory schizophrenia. Psychiatr Serv. 2007;58(7):983–990.
   PubMed Web of Science ®Google Scholar
• Kasteridis P, Ride J, Gutacker N, et al. Association between antipsychotic polypharmacy and outcomes for people with serious mental illness in England. Psychiatr Serv. 2019;70(8):650–656.
   PubMed Web of Science ®Google Scholar
• Velligan DI, Carroll C, Lage MJ, et al. Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations. Psychiatr Serv. 2015;66(2):127–133.
   PubMed Web of Science ®Google Scholar
• Boskailo E, Malkoc A, McCurry DB, et al. Assessment of inpatient psychiatric readmission risk among patients discharged on an antipsychotic polypharmacy regimen: A retrospective cohort study. Acta Med Acad. 2017;46(2):133–144.
   PubMedGoogle Scholar
• Karagianis J, Rosenbluth M, Tohen M, et al. Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools. Curr Med Res Opin. 2007;23(10):2551–2557.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686–693.
   PubMed Web of Science ®Google Scholar
• Taipale H, Mehtälä J, Tanskanen A, et al. Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia-a nationwide study with 20-year follow-up. Schizophr Bull. 2018;44(6):1381–1387.
   PubMed Web of Science ®Google Scholar
• Galling B, Roldán A, Rietschel L, et al. Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. Expert Opin Drug Saf. 2016;15(5):591–612. .
   PubMed Web of Science ®Google Scholar
• Swartz MS, Wagner HR, Swanson JW, et al. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis. 2006;194(3):164–172.
   PubMed Web of Science ®Google Scholar
• Kyriacou DN, Lewis RJ. Confounding by indication in clinical research. JAMA. 2016;316(17):1818–1819.
   PubMed Web of Science ®Google Scholar
• Terevnikov V, Joffe G, Stenberg JH. Randomized controlled trials of add-on antidepressants in schizophrenia. Int J Neuropsychopharmacol. 2015;18(9):pyv049.
   PubMed Web of Science ®Google Scholar
• Citrome L. Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? Expert Rev Neurother. 2009;9(1):55–71.
   PubMed Web of Science ®Google Scholar
• Citrome L. Adding lithium or anticonvulsants to antipsychotics for the treatment of schizophrenia: useful strategy or exercise in futility? J Clin Psychiatry. 2009;70(6):932–933.
   PubMed Web of Science ®Google Scholar
• Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand. 2002;106(5):323–330.
   PubMed Web of Science ®Google Scholar
• Centorrino F, Goren JL, Hennen J, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry. 2004;161(4):700–706.
   PubMed Web of Science ®Google Scholar
• Sakurai H, Bies RR, Stroup ST, et al. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophr Bull. 2013;39(3):564–574.
   PubMed Web of Science ®Google Scholar
• Campos Mendes J, Azeredo-Lopes S, Cardoso G. Patterns of antipsychotics’ prescription in Portuguese acute psychiatric wards: A cross-sectional study. Psychiatry Res. 2016;246:142–148.
   PubMed Web of Science ®Google Scholar
• Barnes TR, Paton C. Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs. 2011;25(5):383–399.
   PubMed Web of Science ®Google Scholar
• Gibson AP, Patel NC, Lauriello J, et al. Antipsychotic combinations: blind step or logical? Curr Psychiatry. 2008;7(7):41–53.
   Google Scholar
• Siskind DJ, Lee M, Ravindran A, et al. Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis. Aust N Z J Psychiatry. 2018;52(8):751–767.
   PubMed Web of Science ®Google Scholar
• Barber S, Olotu U, Corsi M, et al. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Cochrane Database Syst Rev. 2017;3(3):CD006324.
   PubMedGoogle Scholar
• Jiménez-Cornejo M, Munizaga G, Aceituno D. Does adding a second antipsychotic to clozapine improve clinical response in resistant schizophrenia? Medwave. 2016;16(Suppl5):e6614.
   PubMedGoogle Scholar
• Zimbron J, Khandaker GM, Toschi C, et al. A systematic review and meta-analysis of randomised controlled trials of treatments for clozapine-induced obesity and metabolic syndrome. Eur Neuropsychopharmacol. 2016;26(9):1353–1365.
   PubMed Web of Science ®Google Scholar
• Smith RL, Tveito M, Kyllesø L, et al. Impact of antipsychotic polypharmacy on nonadherence of oral antipsychotic drugs - A study based on blood sample analyses from 24,239 patients. Eur Neuropsychopharmacol. 2020;37:64–69.
   PubMed Web of Science ®Google Scholar
• Schoretsanitis G, Kane JM, Correll CU, et al. Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the american society of clinical psychopharmacology and the therapeutic drug monitoring task force of the arbeitsgemeinschaft für neuropsychopharmakologie und pharmakopsychiatrie. J Clin Psychiatry. 2020;81(3):19cs13169.
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 1995;21(3):419–429.
   PubMed Web of Science ®Google Scholar
• Haycox A. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. Pharmacoeconomics. 2005;23(Suppl S1):3–16.
   PubMedGoogle Scholar
• Samara MT, Dold M, Gianatsi M, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry. 2016;73(3):199–210.
   PubMed Web of Science ®Google Scholar
• Bioque M, Parellada E, García-Rizo C, et al. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study. Eur Psychiatry. 2020;63(1):e71.
   PubMed Web of Science ®Google Scholar
• Wagner E, Kane JM, Correll CU, et al. Clozapine combination and augmentation strategies in patients with schizophrenia -recommendations from an international expert survey among the treatment response and resistance in psychosis (TRRIP) working group [published online ahead of print, 2020 May 18]. Schizophr Bull. 2020.
   Web of Science ®Google Scholar